Percutaneous transluminal coronary angioplasty (PTCA) versus t-PA
This article was originally published in Clinica
Executive Summary
The magnitude of PTCA's benefit over thrombolysis for heart attack patients was challenged by data from a subgroup of the GUSTO IIb trial. The results of the trial, which randomised patients to either primary PTCA or the latest t-PA thrombolysis regimen, were presented at the American College of Cardiology annual conference in Orlando last week.